Corporate Profile

We are a microglia-focused company dedicated to improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain’s immune system. Leveraging recent research implicating microglial dysfunction in neurodegenerative diseases, we utilize a precision medicine approach to develop a pipeline of therapeutic candidates that we believe will activate and restore microglial function.

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases
Mar 26, 2024
Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Mar 20, 2024
Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer
Mar 13, 2024
Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting
Events & Presentations
More events are coming soon.
Print Page
Email Alerts
RSS Feeds
Contact IR


You are leaving Vigil Neuroscience, Inc.’s website. You may return to Vigil Neuroscience, Inc.’s website by using the “Back” button on your Web browser toolbar or closing the window to the third-party website that you have opened. Do you wish to continue?